Briakinumab

DB05459InvestigationalProtein Based Therapies

Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated... It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha.

Mechanism: Briakinumab targets and neutralizes interleukin-12 and interleukin-23.
Curator reviewed
Primary indication: Investigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.Curator reviewed
Formula / weight: C₆₃₇₆H₉₈₇₄N₁₇₂₂O₁₉₉₂S₄₄ · 146500.0 Da
Code names: ABT-874

Resolves to

Compound

UNII978I8M0P8XCAS339308-60-0

Clinical / RWD

ATCL04AC09

Targets

P29460IL12BQ9NPF7IL23A

What you can answer from here — as of February 21, 2021

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

686Drug interactionsStructured to mechanism, not free text

8Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 12 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Briakinumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account